AILT
MCID: ANG046
MIFTS: 43

Angioimmunoblastic T-Cell Lymphoma (AILT) malady

Categories: Rare diseases, Cancer diseases, Blood diseases, Immune diseases

Aliases & Classifications for Angioimmunoblastic T-Cell Lymphoma

Aliases & Descriptions for Angioimmunoblastic T-Cell Lymphoma:

Name: Angioimmunoblastic T-Cell Lymphoma 50 56 52
Immunoblastic Lymphadenopathy 50 56
T-Cell Lymphoma, Aild Type 50 56
Lymphogranulomatosis X 50 56
Angioimmunoblastic Lymphadenopathy 69
Aitl 50
Ailt 56

Characteristics:

Orphanet epidemiological data:

56
angioimmunoblastic t-cell lymphoma
Age of onset: Adult;

Classifications:



External Ids:

Orphanet 56 ORPHA86886
ICD10 via Orphanet 34 C86.5
ICD10 33 C86.5

Summaries for Angioimmunoblastic T-Cell Lymphoma

MalaCards based summary : Angioimmunoblastic T-Cell Lymphoma, also known as immunoblastic lymphadenopathy, is related to lymphoma and peripheral t-cell lymphoma, and has symptoms including exanthema An important gene associated with Angioimmunoblastic T-Cell Lymphoma is MME (Membrane Metalloendopeptidase), and among its related pathways/superpathways are Akt Signaling and Signaling events mediated by VEGFR1 and VEGFR2. The drugs Beleodaq and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and bone, and related phenotypes are Decreased cell migration and Increased cell migration

Related Diseases for Angioimmunoblastic T-Cell Lymphoma

Diseases related to Angioimmunoblastic T-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 69)
id Related Disease Score Top Affiliating Genes
1 lymphoma 11.1
2 peripheral t-cell lymphoma 10.5
3 b-cell lymphomas 10.5
4 diffuse large b-cell lymphoma 10.4
5 leukemia 10.3
6 factitious disorder 10.1 KDR MME
7 pure red-cell aplasia 10.1
8 vasculitis 10.1
9 plasma cell leukemia 10.1
10 pneumonia 10.1
11 t-cell adult acute lymphocytic leukemia 10.1 IDH2 MME
12 nodular tenosynovitis 10.0 MAF MME
13 sarcomatoid renal cell carcinoma 10.0 KDR MME
14 follicular lymphoma 10.0
15 hematopoietic stem cell transplantation 10.0
16 cervicitis 10.0
17 polyarteritis nodosa 10.0
18 mycosis fungoides 10.0
19 myelofibrosis 10.0
20 thrombocytopenia 10.0
21 chronic lymphocytic leukemia 10.0
22 endotheliitis 10.0
23 methotrexate-associated lymphoproliferative disorders 10.0
24 spondylitis 10.0
25 mesothelioma, somatic 9.9 CXCL13 MME
26 benign familial neonatal epilepsy 9.9 KDR VEGFC
27 metagonimiasis 9.9 KDR VEGFC
28 gastroesophageal junction adenocarcinoma 9.8 IDH2 VEGFC
29 cardiac tamponade 9.8
30 t-cell leukemia 9.8
31 glomerulonephritis 9.8
32 autoimmune hemolytic anemia 9.8
33 granuloma annulare 9.8
34 urticaria 9.8
35 lymphadenitis 9.8
36 lupus erythematosus 9.8
37 systemic lupus erythematosus 9.8
38 hemolytic anemia 9.8
39 squamous cell carcinoma 9.8
40 evans' syndrome 9.8
41 hodgkin lymphoma 9.8
42 hemophagocytic lymphohistiocytosis 9.8
43 pemphigus 9.8
44 membranous nephropathy 9.8
45 hepatitis 9.8
46 antiphospholipid syndrome 9.8
47 gingivitis 9.8
48 hypereosinophilic syndrome 9.8
49 adult t-cell leukemia 9.8
50 purpura 9.8

Graphical network of the top 20 diseases related to Angioimmunoblastic T-Cell Lymphoma:



Diseases related to Angioimmunoblastic T-Cell Lymphoma

Symptoms & Phenotypes for Angioimmunoblastic T-Cell Lymphoma

UMLS symptoms related to Angioimmunoblastic T-Cell Lymphoma:


exanthema

GenomeRNAi Phenotypes related to Angioimmunoblastic T-Cell Lymphoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.13 ITK KDR VEGFC
2 Increased cell migration GR00055-A-3 8.8 ITK KDR VEGFC

MGI Mouse Phenotypes related to Angioimmunoblastic T-Cell Lymphoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.1 CXCL13 ITK KDR MAF MME VEGFC

Drugs & Therapeutics for Angioimmunoblastic T-Cell Lymphoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Beleodaq 17 46 BELINOSTAT Spectrum Pharmaceuticals Approved July 2014

Drugs for Angioimmunoblastic T-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 344)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 23214-92-8 31703
2
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
3
Etoposide Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 33419-42-0 36462
4
Methotrexate Approved Phase 4,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
5
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
6
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
7
Mechlorethamine Approved Phase 4,Phase 1,Phase 2 51-75-2 4033
8
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
9
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-02-2 5743
10
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
11
Ifosfamide Approved Phase 4,Phase 1,Phase 2 3778-73-2 3690
12
Epirubicin Approved Phase 4 56420-45-2 41867
13
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 1,Early Phase 1 58-05-9 54575, 6560146 143
14
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
15
Doxil Approved June 1999 Phase 4,Phase 3,Phase 1,Phase 2 31703
16
Pirarubicin Investigational Phase 4 72496-41-4
17 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
19 Folic Acid Antagonists Phase 4,Phase 2,Phase 1,Early Phase 1
20 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
21 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 1,Early Phase 1
22 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
24 Hormones Phase 4,Phase 3,Phase 2,Phase 1
25 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
26 Vitamin B Complex Phase 4,Phase 2,Phase 1,Early Phase 1
27 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Etoposide phosphate Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
29 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
32 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 1,Phase 2
33 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
34 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
38 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Dexamethasone acetate Phase 4,Phase 3,Phase 2 1177-87-3
40 Dexamethasone 21-phosphate Phase 4,Phase 3,Phase 2
41 Isophosphamide mustard Phase 4,Phase 1,Phase 2
42 BB 1101 Phase 4,Phase 3,Phase 2
43 Folate Nutraceutical Phase 4,Phase 2,Phase 1,Early Phase 1
44 Vitamin B9 Nutraceutical Phase 4,Phase 2,Phase 1,Early Phase 1
45
Cytarabine Approved, Investigational Phase 3,Phase 1,Phase 2 147-94-4 6253
46
Melphalan Approved Phase 2, Phase 3,Phase 1 148-82-3 4053 460612
47
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 498142 38904
48
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
49
Fludarabine Approved Phase 2, Phase 3, Phase 1 21679-14-1, 75607-67-9 30751
50
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 55-98-1 2478

Interventional clinical trials:

(show top 50) (show all 248)
id Name Status NCT ID Phase
1 CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Recruiting NCT01746992 Phase 4
2 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Recruiting NCT02533700 Phase 4
3 Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP Unknown status NCT00725231 Phase 3
4 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3
5 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3
6 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3
7 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
8 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3
9 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
10 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3
11 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3
12 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
13 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3
14 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
15 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3
16 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3
17 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3
18 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3
19 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3
20 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
21 Comparison of Two Salvage Chemotherapy Regimens Before Autologous Stem Cell Transplantation With or Without Maintenance Rituximab in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma Active, not recruiting NCT00078949 Phase 3
22 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3
23 Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma Unknown status NCT00958854 Phase 2
24 Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma Unknown status NCT01336933 Phase 2
25 Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That is Resistant to Chemotherapy Unknown status NCT01035463 Phase 1, Phase 2
26 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2
27 Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma Unknown status NCT00363090 Phase 1, Phase 2
28 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Unknown status NCT00621036 Phase 2
29 Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders Unknown status NCT00008307 Phase 2
30 Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders Unknown status NCT00740467 Phase 2
31 Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymp Completed NCT02273739 Phase 1, Phase 2
32 A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma Completed NCT00169156 Phase 2
33 RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas Completed NCT01198665 Phase 1, Phase 2
34 Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma Completed NCT00901147 Phase 2
35 Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma Completed NCT01466881 Phase 2
36 506U78 in Treating Patients With Lymphoma Completed NCT00005080 Phase 2
37 Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Completed NCT00601718 Phase 1, Phase 2
38 Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Completed NCT00006473 Phase 2
39 Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma Completed NCT00131937 Phase 2
40 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2
41 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed NCT01326702 Phase 1, Phase 2
42 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Completed NCT01110135 Phase 2
43 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2
44 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2
45 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2
46 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT01427881 Phase 2
47 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer Completed NCT00049504 Phase 2
48 Combination Chemotherapy in Treating Older Patients With Non-Hodgkin's Lymphoma Completed NCT00039351 Phase 2
49 SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma Completed NCT00787527 Phase 1, Phase 2
50 Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment Completed NCT00436618 Phase 2

Search NIH Clinical Center for Angioimmunoblastic T-Cell Lymphoma

Genetic Tests for Angioimmunoblastic T-Cell Lymphoma

Anatomical Context for Angioimmunoblastic T-Cell Lymphoma

MalaCards organs/tissues related to Angioimmunoblastic T-Cell Lymphoma:

39
T Cells, B Cells, Bone, Bone Marrow, Skin, Lymph Node, Kidney

Publications for Angioimmunoblastic T-Cell Lymphoma

Articles related to Angioimmunoblastic T-Cell Lymphoma:

(show top 50) (show all 304)
id Title Authors Year
1
Using Murine Models to Investigate Tumor-Lymphoid Interactions: Spotlight on Chronic Lymphocytic Leukemia and Angioimmunoblastic T-Cell Lymphoma. ( 28512625 )
2017
2
Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin. ( 28082343 )
2017
3
Angioimmunoblastic T-cell Lymphoma Associated with IgA Nephropathy. ( 28050005 )
2017
4
The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. ( 27983760 )
2016
5
Expression of multiple cytokines and chemokine receptor 4 in angioimmunoblastic T-cell lymphoma with abundant plasma cell infiltration involving the skin. ( 27072191 )
2016
6
Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma. ( 27402335 )
2016
7
Clinicopathologic Analysis of Angioimmunoblastic T-cell Lymphoma With or Without RHOA G17V Mutation Using Formalin-fixed Paraffin-embedded Sections. ( 27158755 )
2016
8
Clinical features, outcome and prognostic factors of 87 patients with angioimmunoblastic T cell lymphoma in Taiwan. ( 27095042 )
2016
9
Angioimmunoblastic T-Cell Lymphoma in a Patient with Klinefelter Syndrome. ( 27452959 )
2016
10
Treatment of Cutaneous Angioimmunoblastic T-Cell Lymphoma With Fractionated Carbon Dioxide Laser. ( 26885834 )
2016
11
Value of interim FDG PET/CT for predicting outcome of patients with angioimmunoblastic T-cell lymphoma. ( 27718766 )
2016
12
The curious origins of angioimmunoblastic T-cell lymphoma. ( 27177312 )
2016
13
Chromosomal translocation t(1;22)(q21;q11) in a patient with angioimmunoblastic T-cell lymphoma. ( 27771835 )
2016
14
Response to 5-azacytidine in a patient with TET2-mutated angioimmunoblastic T-cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphoma. ( 27353473 )
2016
15
An analysis of MYC and EBV in diffuse large B-cell lymphomas associated with angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma not otherwise specified. ( 26772393 )
2016
16
Cytomegalovirus Pneumonia after Anti-CC-chemokine Receptor 4 Monoclonal Antibody (Mogamulizumab) Therapy in an Angioimmunoblastic T-cell Lymphoma Patient. ( 26984089 )
2016
17
Expression of the significance of silent information regulator type-1 in Angioimmunoblastic T-cell lymphoma is greater association with tumorigenesis and has strong implications for adverse prognosis. ( 27124741 )
2016
18
A phase II clinical trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic T-cell lymphoma. An NCRI clinical trial. CRUK number C17050/A5320. ( 27001186 )
2016
19
The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development. ( 27956631 )
2016
20
A Case of Cutaneous Epstein-Barr Virus-Associated Diffuse Large B-Cell Lymphoma in an Angioimmunoblastic T-Cell Lymphoma. ( 27904290 )
2016
21
p-MAPK1 expression associated with poor prognosis in angioimmunoblastic T-cell lymphoma patients. ( 26915336 )
2016
22
Discussion of 18F-FDG PET/CT imaging characteristics and diagnostic values of angioimmunoblastic T-cell lymphoma. ( 27832711 )
2016
23
Anti-CCR4 Monoclonal Antibody Mogamulizumab Followed by the GDP (Gemcitabine, Dexamethasone and Cisplatin) Regimen in Primary Refractory Angioimmunoblastic T-Cell Lymphoma. ( 27226129 )
2016
24
Angioimmunoblastic T-cell Lymphomas With the RHOA p.Gly17Val Mutation Have Classic Clinical and Pathologic Features. ( 26574844 )
2016
25
Pneumocystis pneumonia associated with peripheral lymphocytosis in angioimmunoblastic T-cell lymphoma, resembling immune reconstitution syndrome. ( 27544629 )
2016
26
A Clinicopathologic Study of Lennert Lymphoma and Possible Prognostic Factors: The Importance of Follicular Helper T-cell Markers and the Association With Angioimmunoblastic T-cell Lymphoma. ( 27428734 )
2016
27
Cutaneous Presentation of Angioimmunoblastic T-Cell Lymphoma: A Harbinger of Poor Prognosis? ( 28031140 )
2016
28
Angioimmunoblastic T-cell lymphoma with a clonal plasma cell proliferation that underwent immunoglobulin isotype switch in the skin, coinciding with cutaneous disease progression. ( 27596815 )
2016
29
Elevated absolute monocyte count predicts unfavorable outcomes in patients with angioimmunoblastic T-cell lymphoma. ( 26764222 )
2016
30
BCL6 locus is hypermethylated in angioimmunoblastic T-cell lymphoma. ( 27921272 )
2016
31
A difficult case of angioimmunoblastic T-cell lymphoma to diagnose. ( 26969779 )
2016
32
Molecular mechanisms of angioimmunoblastic T-cell lymphoma development. ( 27599421 )
2016
33
How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future. ( 27982416 )
2016
34
Bortezomib-based chemotherapy to treat refractory angioimmunoblastic T-cell lymphoma: A case report and review of the literature. ( 26998168 )
2016
35
Saggy skin as a presenting sign of angioimmunoblastic T-cell lymphoma. ( 26620295 )
2016
36
Angioimmunoblastic T-cell lymphoma mimicking dermatomyositis. ( 26898515 )
2016
37
Angioimmunoblastic T-cell lymphoma suspected to recur in the cranium after complete remission: A case report. ( 26797482 )
2016
38
Histiocytic Infiltrate in Angioimmunoblastic T-Cell Lymphoma with Cutaneous Nodules and Progressive Ulceration: A Rare Manifestation. ( 27274643 )
2016
39
Successful treatment of angioimmunoblastic T-cell lymphoma with clarithromycin. ( 27382561 )
2016
40
Immunophenotypic and diagnostic characterization of angioimmunoblastic T-cell lymphoma by advanced flow cytometric technology. ( 27105079 )
2016
41
Angioimmunoblastic T Cell Lymphoma Mimicking Chronic Urticaria. ( 26925107 )
2016
42
Angioimmunoblastic T-cell lymphoma. ( 25791860 )
2015
43
Follicular Dendritic Cell Meshwork in Angioimmunoblastic T-Cell Lymphoma Is Characterized by Accumulation of CXCL13(+) Cells. ( 26490517 )
2015
44
Lymph node involvement by mycosis fungoides and SAczary syndrome mimicking angioimmunoblastic T-cell lymphoma. ( 26193796 )
2015
45
Methotrexate-associated lymphoproliferative disorder: Sequential development of angioimmunoblastic T-cell lymphoma-like lymphoproliferation in the lymph nodes and diffuse large B-cell lymphoma in the skin in the same patient. ( 26105783 )
2015
46
Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets. ( 26045291 )
2015
47
Skin lesions and neutrophilic leukemoid reaction in a patient with angioimmunoblastic T-cell lymphoma: a case report and review of the literature. ( 26185653 )
2015
48
Angioimmunoblastic T-cell lymphoma with coexisting plasma cell myeloma: a case report and review of the literature. ( 25816919 )
2015
49
Cerebellar EBV-associated diffuse large B cell lymphoma following angioimmunoblastic T cell lymphoma. ( 27559423 )
2015
50
IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. ( 26268241 )
2015

Variations for Angioimmunoblastic T-Cell Lymphoma

Expression for Angioimmunoblastic T-Cell Lymphoma

Search GEO for disease gene expression data for Angioimmunoblastic T-Cell Lymphoma.

Pathways for Angioimmunoblastic T-Cell Lymphoma

Pathways related to Angioimmunoblastic T-Cell Lymphoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.77 CXCL13 ITK KDR VEGFC
2
Show member pathways
11.22 KDR VEGFC
3 11.1 KDR VEGFC
4 10.95 ITK KDR VEGFC
5
Show member pathways
10.16 KDR VEGFC

GO Terms for Angioimmunoblastic T-Cell Lymphoma

Biological processes related to Angioimmunoblastic T-Cell Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.26 KDR VEGFC
2 positive regulation of endothelial cell proliferation GO:0001938 9.16 KDR VEGFC
3 peptidyl-tyrosine autophosphorylation GO:0038083 8.96 ITK KDR
4 cytokine production GO:0001816 8.62 ITK MAF

Sources for Angioimmunoblastic T-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....